Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer

References

• Biganzoli L, Wildiers H, Oakman C, et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol. 2012;13(4):e148–e160.
   PubMed Web of Science ®Google Scholar
• Early and locally advanced breast cancer: diagnosis and management NICE guideline [Internet]; 2018; [cited 2020 Aug 14]. Available from: www.nice.org.uk/guidance/ng101
   Google Scholar
• Sestak I, Buus R, Cuzick J, et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4(4):591–553.
   PubMed Web of Science ®Google Scholar
• Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55–65.
   PubMed Web of Science ®Google Scholar
• Wishart GC, Azzato EM, Greenberg DC, et al. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 2010;12(1):1–10.
   PubMed Web of Science ®Google Scholar
• Stemmer SM, Steiner M, Rizel S, et al. Clinical outcomes in ER + HER2 -node-positive breast cancer patients who were treated according to the recurrence score results: evidence from a large prospectively designed registry. NPJ Breast Cancer. 2017;3(1):1–7.
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Barlow WE, Gonzalez-Angulo AM, et al. Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes. Contemp Clin Trials. 2013;34(1):1–9.
   PubMed Web of Science ®Google Scholar
• Kalinsky K, Barlow WE, Gralow JR, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336–2347.
   PubMed Web of Science ®Google Scholar
• Kalinsky K. Predicting chemotherapy benefit in node-positive breast cancer with the 21-gene test: the Oncotype DX Breast Recurrence Score® Test. San Antonio Breast Cancer Conference; 2021.
   Google Scholar
• National Institute for Health and Care Excellence. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer. London (UK); 2018.
   Google Scholar
• Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726–3734.
   PubMed Web of Science ®Google Scholar
• Hall PS, Smith A, Hulme C, et al. Value of information analysis of multiparameter tests for chemotherapy in early breast cancer: the OPTIMA prelim trial. Value Health. 2017;20(10):1311–1318.
   PubMed Web of Science ®Google Scholar
• Ward S, Scope A, Rafia R, et al. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2013;17(44):1–302.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal [Internet]; 2013. Available from: https://www.nice.org.uk/process/pmg9/chapter/foreword
   Google Scholar
• Curtis Lesley A, Burns A. Unit costs of health and social care 2018. Project report. Canterbury (UK): University of Kent; 2018.
   Google Scholar
• Kalinsky K, Barlow WE, Gralow JR. Distant-disease free interval in participants with 1–3 positive lymph nodes, hormone receptor-positive and HER2-negative breast cancer with recurrence score < or = 25 randomized to endocrine therapy +/- chemotherapy: SWOG S1007 (RxPONDER). San Antonio (TX): San Antonio Breast Cancer Symposium; 2021.
   Google Scholar
• De Bock GH, Putter H, Bonnema J, et al. The impact of loco-regional recurrences on metastatic progression in early-stage breast cancer: a multistate model. Breast Cancer Res Treat. 2009;117(2):401–408.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Borgonovo K, Cabiddu M, et al. Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis. Breast Cancer Res Treat. 2012;135(2):335–346.
   PubMed Web of Science ®Google Scholar
• Office for National Statistics. National life tables 2016–2018, United Kingdom [Internet]; 2019; [cited 2021 Feb 3]. Available from: https://www.ons.gov.uk/releases/nationallifetablesuk2016to2018
   Google Scholar
• Ellis P, Barrett-Lee P, Johnson L, et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet. 2009;373(9676):1681–1692.
   PubMed Web of Science ®Google Scholar
• Sledge GW, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020;6(1):116–124.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia. London (UK); 2018.
   Google Scholar
• Lidgren M, Wilking N, Jönsson B, et al. Health related quality of life in different states of breast cancer. Qual Life Res. 2007;16(6):1073–1081.
   PubMed Web of Science ®Google Scholar
• Campbell HE, Epstein D, Bloomfield D, et al. The cost-effectiveness of adjuvant chemotherapy for early breast cancer: a comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. Eur J Cancer. 2011;47(17):2517–2530.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia. London; 2011.
   Google Scholar
• Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value Health. 2008;11(7):1131–1143.
   PubMed Web of Science ®Google Scholar
• London Cancer Alliance West and South. LCA breast cancer clinical guidelines [Internet]; 2016; [cited 2022 Feb 18]. Available from: http://rmpartners.cancervanguard.nhs.uk/wp-content/uploads/2017/03/lca-breast-cancer-clinical-guidelines-october-2013-updated-march-2016-.pdf
   Google Scholar
• NHS Thames Valley. Chemotherapy regimens breast cancer [Internet]; 2022; [cited 2022 Feb 18]. Available from: http://tvscn.nhs.uk/wp-content/uploads/2018/12/Breast-4.2-November-2018.pdf
   Google Scholar
• London Cancer Alliance West and South. Breast pathway group FEC75 in early breast cancer [Internet]; 2016; [cited 2022 Feb 18]. Available from: https://rmpartners.nhs.uk/wp-content/uploads/2017/03/LCA-Breast-FEC75-EBC-November-2014.pdf
   Google Scholar
• London Cancer Alliance West and South. Breast pathway group – EC × 4 – Docetaxel × 4: epirubicin & cyclophosphamide followed by docetaxel in early breast cancer [Internet]; 2016; [cited 2022 Feb 18]. Available from: https://rmpartners.nhs.uk/wp-content/uploads/2017/03/LCA-Breast-EC-Docetaxel-EBC-November-2014.pdf
   Google Scholar
• Department of Health and Social Care. Drugs and pharmaceutical electronic market information tool (eMIT) [Internet]; 2021; [cited 2022 Jan 7]. Available from: https://www.gov.uk/government/publications/drugs-and-pharmaceutical-electronic-market-information-emit
   Google Scholar
• National Institute for Health and Care Excellence. British National Formulary [Internet]; 2020; [cited 2022 Jan 7]. Available from: https://bnf.nice.org.uk/
   Google Scholar
• Kurosky SK, Mitra D, Zanotti G, et al. Treatment patterns and outcomes of patients with metastatic ER+/HER-2– breast cancer: a multicountry retrospective medical record review. Clin Breast Cancer. 2018;18(4):e529–e538.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer [Internet]. London (UK); 2019. Available from: https://www.nice.org.uk/guidance/ta593
   Google Scholar
• National Institute for Health and Care Excellence. Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer; 2019.
   Google Scholar
• National Institute for Health and Care Excellence. Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer [Internet]; 2017. Available from: https://www.nice.org.uk/guidance/ta495
   Google Scholar
• Karnon J, Kerr GR, Jack W, et al. Health care costs for the treatment of breast cancer recurrent events: Estimates from a UK-based patient level analysis. Br J Cancer. 2007;97(4):479–485.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Mahmoud D, Kucmin-Bemelmans IT, et al. Economic burden associated with acute myeloid leukemia treatment. Expert Rev Hematol. 2015;9(1):79–89.
   PubMed Web of Science ®Google Scholar
• Hinde S, Theriou C, May S, et al. The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer. Heal Policy Technol. 2019;8(1):75–83.
   Web of Science ®Google Scholar
• Roberts MC, Miller DP, Shak S, et al. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and oncotype DX recurrence score results in the SEER database. Breast Cancer Res Treat. 2017;163(2):303–310.
   PubMed Web of Science ®Google Scholar
• Cardoso F, van 't Veer L, Poncet C, et al. MINDACT: long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients. J Clin Oncol. 2020;38(15 Suppl.):506.
   Web of Science ®Google Scholar
• Bloomfield DJ, Arbon A, Cox J, et al. Patient/oncologist decisions about adjuvant chemotherapy in ER + ve, HER2-ve early breast cancer following endopredict testing. J Clin Oncol. 2017;35(15 Suppl.):e12002.
   Web of Science ®Google Scholar
• Wang SY, Dang W, Richman I, et al. Cost-effectiveness analyses of the 21-gene assay in breast cancer: systematic review and critical appraisal. J Clin Oncol. 2018;36(16):1619–1627.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN guidelines: breast cancer, version 2.2021. Plymouth Meeting (PA); 2021.
   Google Scholar